

3 August 2022
ASX Code: MXC
LSE Code: MXC

Issue of Shares – Cleansing Notice

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that it has issued the following fully paid ordinary shares (**Shares**) in the Company today:

1. 21,511,545 Shares were issued to Mercer Street Global Opportunity Fund, LLC in accordance with the Convertible Securities Agreement dated 29 July 2022.
2. 15,000,000 Shares were issued to employees/consultants for services rendered, in lieu of cash settlement.

Cleansing Notice:

Pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**), the Company gives notice in relation to the Shares issued above, that:

- (a) the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act;
- (b) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company;
- (c) as at the date of this Notice, the Company has complied with section 674 of the Corporations Act; and
- (d) as at the date of this Notice, there is no information to be disclosed which is "excluded information" as defined in subsection 708A(7) of the Corporations Act that is reasonable for investors and their professional advisors to find in a disclosure document.

— Ends —

Authorised for release by David Lim, Company Secretary, further information, please contact:

MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.com.au

UK Broker – Turner Pope
Andy Thacker
+44 203 657 0050
info@turnerpope.com

MGC Pharmaceuticals Ltd
David Lim
Company Secretary
+61 8 6382 3390
info@mgcpharma.com.au

UK PR Advisors – Tavistock
Tim Pearson/Charles Vivian
+44 207 920 3150
mgcpharma@tavistock.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    